Novo Nordisk A/S vs Xpeng Inc - ADR — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Xpeng Inc - ADR trades at $13.38 (market cap $12.96B). The key difference: Novo Nordisk A/S is far larger — about 17× Xpeng Inc - ADR's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| NVO | XPEV | |
|---|---|---|
Market Cap | $220.53B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $71.70 | $28.07 |
52-Week Low | $35.29 | $12.09 |
Enterprise Value | $239.49B | $15.07B |
Dividend Yield | 3.63% | — |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →